Skip to main content
EKTAY logo

Elekta AB (publ) (EKTAY) Stock Price & Analysis

Elekta AB (publ) (EKTAY) — price $6.04 (-2.27%), as of the Nov 19, 2026 trading session; market cap $2.31B.

Educational signal · not a buy or sell recommendation · How to read this

$6.04 −$0.14 (-2.27%) Market Cap $2.31B

Elekta AB (publ) · EKTAY

Elekta AB (publ) is a Swedish medical technology company specializing in clinical solutions for cancer and brain disorders. Their offerings include radiation therapy systems, neurosurgery products, and treatment management software.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • UFPT · UFP Technologies, Inc. · 87 /100
  • ESTA · Establishment Labs Holdings Inc. · 35 /100
  • IRTC · iRhythm Technologies, Inc. · 33 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$6.04
Change on the day-2.27%
52-week range$4.35 – $6.93
Market capitalisation$2.31B—
Price / earnings (trailing)76.25
Shares traded on the day5.0K

Price & events

Other perspectives

Council score for Elekta AB (publ) (EKTAY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Weak
ROE Negative
Gross Margin Neutral

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Elekta AB (publ) (EKTAY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Elekta AB (publ) (EKTAY) is the company analyzed here. It employs 4,102 people and is led by Jakob Just-Bomholt. In Q1 FY2027 it reported revenue of kr3.54B and net income of kr264M. The market values it at $2.31B.

2 · Latest results

What do the latest results show for Elekta AB (publ) (EKTAY)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of kr3.54B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027kr3.54Bkr264Mkr0.69 (diluted)
Q4 FY2026kr4.77B-kr868M-kr2.30 (diluted)
Q3 FY2026kr4.06Bkr10Mkr0.03 (diluted)
Q2 FY2026kr4.07Bkr230Mkr0.60 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Elekta AB (publ) (EKTAY)?

Short answer · as of

The distress and quality screens read Altman Z 1.41 · Piotroski F 5. Trailing ratios: ROE -4.7% · ROA -1.4% · current ratio 0.86 · earnings yield -1.5% · free-cash-flow yield 10.5%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.41 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-4.7%) — the business is not currently generating profit on shareholder capital.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EKTAY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported EKTAY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: EKTAY Stock

These answers are editorial: 1 of these 8 answers is drawn from the EKTAY research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is EKTAY a good stock to buy?

Stock Expert AI does not rate EKTAY buy, sell or hold. Elekta AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the EKTAY stock price today?

The last price recorded for Elekta AB (publ) (EKTAY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about EKTAY stock?

Analyst coverage of EKTAY stock is limited due to its OTC listing and ADR status. However, analysts generally recognize Elekta's established position in the radiation therapy and neurosurgery markets.

What are the key factors to evaluate for EKTAY?

Evaluate EKTAY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Emerging Markets Expansion: Expanding into emerging markets, such as China and India, offers significant growth potential. Not financial advice.

How frequently does EKTAY data refresh on this page?

EKTAY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven EKTAY's recent stock price performance?

Elekta AB (publ) (EKTAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established market position in radiation therapy and neurosurgery. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider EKTAY overvalued or undervalued right now?

The trailing P/E of Elekta AB (publ) (EKTAY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research EKTAY before investing?

Before investing in Elekta AB (publ) (EKTAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.